Ningbo Tianyi Medical's share repurchase ratio reaches 1%, with nearly 60 million yuan spent.

Log in to the Sina Finance APP and search for [information disclosure] to see more evaluation levels.

Ningbo Tianyi Medical Instrument Co., Ltd. (hereinafter referred to as “Ningbo Tianyi Medical”) announced on March 24, 2026, that as of March 23, 2026, the total shares repurchased by the company have reached 1% of the total share capital, with the repurchase amount close to the lower limit of the plan. This is the first significant progress disclosure since the company launched its share repurchase plan in January 2026.

Background of the Repurchase Plan

On January 12, 2026, the second meeting of the fourth board of directors of Ningbo Tianyi Medical reviewed and approved the repurchase plan, intending to use its own funds and bank loans to repurchase A-shares through centralized bidding transactions for the implementation of equity incentives or employee stock ownership plans. According to the plan, the repurchase price shall not exceed 65 yuan/share (inclusive), and the total amount of repurchase funds is between 60 million and 120 million yuan (both inclusive). Based on the upper price limit and the upper and lower limits of funds, it is estimated that the number of shares to be repurchased will be between 923,077 and 1,846,154 shares, accounting for 1.57% to 3.13% of the company’s current total share capital. The repurchase period shall not exceed 12 months from the date of board approval.

Progress of the Repurchase Implementation

The announcement shows that as of March 23, 2026, the company has cumulatively repurchased 1,034,500 shares through a dedicated repurchase securities account, accounting for 1% of the company’s total share capital. The total transaction amount for this repurchase is 59.9865 million yuan (excluding transaction fees), and the calculated average repurchase price is about 58 yuan/share, which is below the upper price limit of 65 yuan/share.

In terms of the repurchase progress, the amount repurchased of 59.9865 million yuan is close to the lower limit of the plan of 60 million yuan, completing 99.98% of the lower limit funds; the number of shares repurchased is 1,034,500, exceeding the estimated lower limit of 923,077 shares by about 12.07%, accounting for 56.03% of the estimated upper limit of 1,846,154 shares.

Compliance Statement and Future Plans

Ningbo Tianyi Medical emphasized in the announcement that this repurchase strictly complies with the “Rules on Share Buybacks of Listed Companies (2025 Revision)” and “Self-Regulatory Guidelines No. 9 for Listed Companies on the Shenzhen Stock Exchange - Share Buybacks (2025 Revision)” and other regulations. Specifically, the company did not conduct repurchases during prohibited periods such as major decision-making and disclosure periods, and the entrusted price for centralized bidding transactions did not reach the daily limit price for increases, nor were orders placed during opening/closing calls and on days without price limits.

The company stated that it will continue to implement the repurchase plan based on market conditions within the remaining repurchase period and will fulfill its information disclosure obligations in a timely manner according to relevant regulations. Investors can pay attention to the company’s subsequent announcements for updates on the repurchase progress.

Disclaimer: The market has risks, and investment requires caution. This article is automatically published by an AI model based on third-party databases and does not represent the views of Sina Finance. Any information appearing in this article is for reference only and does not constitute personal investment advice. Please refer to the actual announcement for any discrepancies. For inquiries, please contact biz@staff.sina.com.cn.

Click here to view the original announcement >>

Massive information and precise interpretations are available in the Sina Finance APP.

Editor: Xiao Lang Kuai Bao